SCHEMBL277518

SCHEMBL277518

CC(C)CCCC(C)CCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.63
LMNA P02545 1/20 0.56
MAPT P10636 1/20 0.51
GABRP O00591 2/20 0.48
GABRD O14764 2/20 0.48
GABRA1 P14867 2/20 0.48
GABRB1 P18505 2/20 0.48
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA5 P31644 2/20 0.48
GABRA3 P34903 2/20 0.48
GABRA2 P47869 2/20 0.48
GABRB2 P47870 2/20 0.48
GABRA4 P48169 2/20 0.48
GABRE P78334 2/20 0.48
GABRA6 Q16445 2/20 0.48
GABRG1 Q8N1C3 2/20 0.48
GABRG3 Q99928 2/20 0.48
GABRQ Q9UN88 2/20 0.48
CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27601852 1.00 BLM (0.63) BLMLMNAMAPTGABRPGABRD
SCHEMBL5878892 1.00 BLM (0.63) BLMLMNAMAPTGABRPGABRD
SCHEMBL10537164 1.00 BLM (0.63) BLMLMNAMAPTGABRPGABRD
SCHEMBL1116070 1.00 BLM (0.63) BLMLMNAMAPTGABRPGABRD
SCHEMBL7585177 0.95 BLM (0.57) BLMLMNAMAPTGABRPGABRD
SCHEMBL16431369 0.93 BLM (0.55) BLMLMNAMAPTGABRPGABRD
SCHEMBL12970998 0.93 BLM (0.55) BLMLMNAMAPTGABRPGABRD
SCHEMBL16431303 0.93 BLM (0.55) BLMLMNAMAPTGABRPGABRD
SCHEMBL5879060 0.91 BLM (0.63) BLMLMNAMAPTGABRPGABRD
SCHEMBL10599018 0.91 BLM (0.63) BLMLMNAMAPTGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-01-22 US claimed
EP-4565325-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-11 EP claimed
CN-119855613-A Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders 匹兹堡大学高等教育联邦体系 2025-04-18 CN claimed
WO-2024030367-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-02-08 WO claimed
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-01-22 US disclosed
EP-4565325-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-11 EP disclosed
CN-120053660-A Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-120053661-A Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-119855613-A Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders 匹兹堡大学高等教育联邦体系 2025-04-18 CN disclosed
CN-119855607-A Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application 太阳雨林(北京)生物医药有限公司 2025-04-18 CN disclosed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 EP disclosed
US-12213956-B2 Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-02-04 US disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
WO-1991018905-A1 RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY SANKYO COMPANY LIMITED (JP) 1991-12-12 WO disclosed
EP-0460950-A1 Radicicol derivatives, their preparation and their anti-tumour activity Sankyo Company Limited (JP) 1991-12-11 EP disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed
US-4915864-A CARBOXYLIC ACID OR SALTS THEREOF AS SOLUBILIZING AGENT WETTING AGENT FOR GLASS, FIBERS, METALS KAO CORPORATION (JP) 1990-04-10 US disclosed
EP-0296432-A2 Aqueous solution composition of strong alkali and nonionic surface active agent Kao Corporation (JP) 1988-12-28 EP disclosed
US-4257913-A SAID SALT SOLUTIONS CONTAINING A PEPTIZING AGENT AND MANGANESE SALTS OF SATURATED BRANCHED-CHAIN ALIPHATIC MONOCARBOXYLIC ACIDS TENNECO CHEMICALS, INC. (US) 1981-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders HADHB, HADHA, HADH BLM 4663/4885LMNA 1735/4885MAPT 3414/4885
US-12213956-B2 Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids ELOVL6, ELOVL3, CPT1B BLM 3348/4885LMNA 2477/4885MAPT 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.